Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma
Launched by CHENGJUN SUI,MD · Nov 30, 2022
Trial Information
Current as of June 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to predict how well a specific chemotherapy treatment, called GC, will work for patients with intrahepatic cholangiocarcinoma (ICC), a type of cancer that affects the bile ducts in the liver. Researchers will create small, lab-grown versions of patients' tumors, known as organoids, from samples taken during a biopsy. These organoids will help them understand how tumors react to the chemotherapy and identify any genetic factors that might make the cancer resistant to treatment. The goal is to develop a personalized approach to treatment, ensuring that each patient receives the most effective therapy based on their unique tumor characteristics.
To be eligible for this trial, patients need to be between 18 and 80 years old and have a confirmed diagnosis of intrahepatic cholangiocarcinoma. They must also be able to provide written consent and have a biopsy sample available. Participants can expect to contribute to important research that could improve treatment options for future patients with this challenging cancer. It's important to note that the trial is not yet recruiting participants, so interested individuals should keep an eye out for updates.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Histologically confirmed intrahepatic cholangiocarcinoma They are between 18 and 80 years old Written informed and signed consent form Biopsy sample of the intrahepatic bile duct
- Exclusion Criteria:
- • - Under 18, over 80 Informed consent cannot be given Biopsy samples were not available
About Chengjun Sui,Md
Dr. Chengjun Sui, MD, is a dedicated clinical trial sponsor with extensive experience in advancing medical research and development. With a strong focus on innovative therapies and patient-centered approaches, Dr. Sui leads trials that aim to improve healthcare outcomes across various therapeutic areas. His commitment to rigorous scientific standards and ethical practices ensures that all trials are conducted with the utmost integrity, fostering collaboration among multidisciplinary teams and stakeholders. Dr. Sui's expertise and leadership contribute significantly to the progression of clinical research, ultimately aiming to enhance treatment options and improve the lives of patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
chengjun sui, dr.
Principal Investigator
Deputy director
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials